Wednesday, 30 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results · Q3 FY26

Parmax Pharma Q3 FY26 Results: Net Loss of ₹0.7 Cr, Loss Widens

Parmax Pharma Ltd reported a net loss of ₹0.7 Cr for Q3 FY26.

Q3 FY26 at a glance · ₹ crore
MetricQ3 FY26Q2 FY26Q3 FY25
Total income4.32.56.3
Net profit-0.7-2.1-0.4
Operating margin-16.3%-84.0%-6.3%

A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.

Source

BSE results filing, NSE: PARMAX. Figures extracted from the filing.

Read the filing ↗

Parmax Pharma Ltd: key numbers

Share price
₹137.75
Market cap
₹51.54 Cr
Revenue (annual)
₹12.11 Cr
Net profit (annual)
₹-4.16 Cr
P/E (TTM)
-43.1×Sector 49.8×
Promoter holding
64.66%+33.86% QoQ
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Parmax Pharma Ltd

All →
21:38 IST BSE
Other Announcement

Parmax Pharma Other Announcement

Parmax Pharma Ltd filed its quarterly shareholding pattern under Regulation 31. The disclosure reflects changes in promoter status following a previously concluded open offer.

20:52 IST BSE
Annual General Meeting

Parmax Pharma Annual General Meeting

Parmax Pharma Ltd will hold its 32nd Annual General Meeting on September 29, 2026. The meeting will address the adoption of financial statements and director appointments.

21:33 IST BSE
Capital Structure Change

Parmax Pharma Capital Structure Change

Parmax Pharma's promoters acquired shares via preferential allotment. This filing discloses the acquisition of equity stakes by eleven promoter-related entities.

Value
₹8.32 Cr
10:47 IST BSE
Capital Structure Change

Parmax Pharma Capital Structure Change

Promoter group members Dhiren Shah and Sunil Shah acquired 22,80,444 equity shares in Parmax Pharma Ltd. The acquisition occurred via a preferential allotment on August 29, 2026.

16:22 IST BSE
Capital Structure Change

Parmax Pharma Capital Structure Change

Parmax Pharma allotted 31.37 lakh equity shares at Rs. 36.50 each and 21.45 lakh convertible warrants to various non-promoter allottees on a preferential basis.

Value
₹11.45 Cr
17:46 IST BSE
Promoter Reclassification

Parmax Pharma Promoter Reclassification

Parmax Pharma announced the reclassification of its promoters following an open offer and share purchase agreement. Existing promoters will be reclassified under the public category.